Skip to main content
GeneOne Life Science, Inc. logo

GeneOne Life Science, Inc. — Investor Relations & Filings

Ticker · 011000 ISIN · KR7011000007 KO Professional, scientific and technical activities
Open in API
Filings indexed 490 across all filing types
Latest filing 2025-09-04 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 011000

About GeneOne Life Science, Inc.

https://www.genels.com/en/

GeneOne Life Science, Inc. is a biopharmaceutical research and development company specializing in nucleic acid-based biomedicines. The company's core focus is on developing DNA and mRNA vaccines, particularly for emerging infectious diseases, leveraging its rapid development platforms. In therapeutics, GeneOne utilizes a proprietary DNA plasmid delivery technology to enable the expression of recombinant proteins and plasmid-encoded monoclonal antibodies (Plas-mAbs®). This non-viral vector approach is designed to offer a safer and more cost-effective alternative to traditional gene therapies and cell-line derived monoclonal antibody treatments for conditions such as cancers and autoimmune disorders. The company also develops immunomodulatory small molecule drugs. Through its subsidiary, GeneOne possesses cGMP-grade manufacturing capabilities for DNA plasmids, supporting its internal pipeline and contract manufacturing services.

Recent filings

Filing Released Lang Actions
유상증자또는주식관련사채등의발행결과(자율공시)
Share Issue/Capital Change Classification · 100% confidence The document is a regulatory filing from GeneOne Life Science regarding the 'Result of Issuance of Paid-in Capital Increase or Equity-Linked Bonds'. It details the final issuance of common shares through a third-party allocation, including the number of shares, total amount, and payment date. This falls under the category of share issuance and capital changes.
2025-09-04 Korean
유상증자또는주식관련사채등의청약결과(자율공시)
Share Issue/Capital Change Classification · 100% confidence The document is a regulatory filing from GeneOne Life Science regarding the results of a paid-in capital increase (subscription results for third-party allocation). It details the number of shares subscribed, the subscription rate, and the payment schedule. This falls under the category of share issuance and capital changes.
2025-09-03 Korean
소액공모공시서류(지분증권)
Capital/Financing Update Classification · 98% confidence The document is a 'Small-Scale Public Offering Disclosure Document' (소액공모공시서류) filed with the Financial Supervisory Service (FSS) in South Korea. It details a third-party allocation capital increase (유상증자) for GeneLife Science (진원생명과학). Since this is a formal regulatory filing detailing a capital raise (share issuance) that does not require a full securities registration statement due to the small size (under 1 billion KRW), it falls under the category of 'Share Issue/Capital Change'.
2025-08-29 Korean
[기재정정]주요사항보고서(유상증자결정)
Share Issue/Capital Change Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) regarding a 'Decision on Paid-in Capital Increase' (유상증자결정) for Genexine (진원생명과학). It details the issuance of new shares, the purpose of the capital raise (operating funds), the pricing methodology, and the third-party allocation details. This is a formal regulatory filing concerning capital structure changes and share issuance, which falls under the 'Share Issue/Capital Change' category.
2025-08-29 Korean
유상증자신주발행가액(안내공시)
Share Issue/Capital Change Classification · 100% confidence The document is a short announcement regarding the 'fixed issuance price' (확정 발행가액) for a capital increase (유상증자) by GeneOne Life Science. It provides specific pricing details for new shares and references a previous capital increase decision. Since it details the issuance of new shares and capital changes, it falls under the 'Share Issue/Capital Change' category.
2025-08-29 Korean
주요사항보고서(유상증자결정)
Share Issue/Capital Change Classification · 100% confidence The document is a 'Major Matters Report' (주요사항보고서) filed with the Financial Services Commission and the Korea Exchange regarding a decision to issue new shares through a third-party allocation (유상증자결정). This is a formal regulatory filing detailing capital structure changes, specifically a share issuance. According to the provided definitions, 'Share Issue/Capital Change' (SHA) is the correct category for announcements regarding new share issues.
2025-08-22 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.